VacZine Analytics  
MarketVIEW: Zika virus vaccines

Published: February 2016

Zika virus (ZIKV) is a member of the Flaviviridae family that includes several mosquito-borne viruses of major clinical importance, including yellow fever virus, Japanese encephalitis virus and dengue virus. Although widely distributed across West and East Africa and Southeast Asia (46 countries/territories since 2007), ZIKV has only recently been identified as a major cause of disease. In most cases, ZIKV usually causes a mild and often asymptomatic illness. However, neonatal microcephaly and Guillain-Barré syndrome (GBS) have recently emerged as possible (but not definitively confirmed) complications of ZIKV infection. For example, in Brazil, an estimated 1.5 million ZIKV cases have occurred since April 2015 and up to November 2015, 1,248 neonatal microcephaly cases have been reported.

ZIKV will likely to spread to other countries in the region that have Aedes mosquitoes. Autochthonous ZIKV transmission is expected to occur in the US whereby the gulf coast region and Florida are most vulnerable. The WHO declared the Zika virus outbreak a global emergency in February 2016. Many private sector companies and government-funded organizations have started work on developing a Zika vaccine due to the significant global public health concern.

This MarketVIEW product is a comprehensive MS Excel-based model + summary presentation that forecasts the potential commercial value of Zika virus vaccines across endemic (public + private) and travelers’ markets to 2035. The model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, TPP, pricing and penetration estimates for all key commercial segments. LO/BASE/HI forecast scenarios are included based upon a differing pricing justifications. An up to date review is also given for latest disease background and epidemiology, along with current R&D status.

THIS PRODUCT IS A EXECUTIVE PRESENTATION AND THREE FORECAST MODELs

To order please contact your region account manager, buy "on-line" or order direct at: orders@vaczine-analytics.com

CAT No: CONTENTS: PURCHASE:
VAMV068 Click here>>
Choose option:
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW. For UK orders VAT will be added at 20%. Please review the TERMS and CONDITIONS of purchase.

Return to main list>> Questions about this report?






© 2016 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains